The value and cost-effectiveness of bispecific antibodies

Adams said she has seen firsthand the difference that bispecific antibodies have made. “Patients that would have never gotten into remission are getting into remission. Patients that would have never seen the birth of their grandchild are now seeing the birth of their grandchild,” Adams said. Some real-world data are showing slightly reduced efficacy that was seen in clinical trials, Adams said. There is a need for research that would develop comparator data to other therapies, she noted.